Acalabrutinib

Small molecule

Also known as ACP-196

Approvedregulatory verdict

Evidence outlook

Approved: Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, Relapsed/Refractory Chronic Lymphocytic Leukemia

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also in development:Diffuse Large B-Cell Lymphoma · Phase 3 · investigational in the US

Also approved (2)
JP
  • Treatment of relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
Product first approved 2021PMDA
EU
  • Calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).Calquence in combination with venetoclax with or without obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).Calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy.Calquence in combination with bendamustine and rituximab (BR) is indicated for the...
Product first approved 2020EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (17)
Chronic Lymphocytic Leukemia
NCT05057494 · AstraZeneca
2022-09-12 – 2029-04-10 · Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
What this study did
NCT05197192 · German CLL Study Group
2022-04-19 – 2028-05 · Chronic Lymphocytic Leukemia
What this study did
NCT04075292 · AstraZeneca
2020-01-20 – 2027-01-01 · Untreated Chronic Lymphocytic Leukemia
What this study did
NCT04178798 · PETHEMA Foundation
2019-12-09 – 2024-12-03 · Chronic Lymphocytic Leukemia- Binet Staging System
What this study did
Diffuse Large B-Cell Lymphoma
Mantle Cell Lymphoma
NCT02735876 · Acerta Pharma BV
2016-05 – 2020-06 · Mantle Cell Lymphoma
What this study did
Relapsed/Refractory Chronic Lymphocytic Leukemia
NCT04008706 · AstraZeneca
2019-09-17 – 2025-11-04 · Chronic Lymphocytic Leukemia
What this study did
Other / comorbidity
NCT07635511 · The First Affiliated Hospital of Soochow University
2026-06-01 – 2029-05-31 · Hematological Malignancies, Platelet Transfusion Refractoriness (PTR), HLA Antibodies
What this study did
NCT06319456 · Ascentage Pharma Group Inc.
2024-04-07 – 2028-08 · CLL/SLL
What this study did
NCT04647669 · The University of The West Indies
2021-06-01 – 2021-12-31 · Covid19
What this study did
Phase 2/3 (1)
Other / comorbidity
NCT03868722 · Copenhagen University Hospital, Rigshospitalet
2019-10-11 – 2030-07-31 · CLL
What this study did
Phase 2 (79)
Chronic Lymphocytic Leukemia
NCT03516617 · Mayo Clinic
2018-09-10 – 2036-11-11 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT07024706 · AstraZeneca
2026-06-04 – 2033-03-23 · Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
What this study did
NCT07014917 · Zulfa Omer
2025-12-05 – 2032-06-05 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, CLL Variant
What this study did
NCT04941716 · Fred Hutchinson Cancer Center
2023-05-31 – 2031-08-10 · Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
What this study did
NCT05388006 · Mayo Clinic
2023-01-05 – 2031-03-30 · Chronic Lymphocytic Leukemia, Richter Syndrome, Small Lymphocytic Lymphoma
What this study did
NCT07582159 · City of Hope Medical Center
2026-12-19 – 2029-04-14 · Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma
What this study did
NCT04963946 · French Innovative Leukemia Organisation
2021-10-18 – 2028-08-01 · Untreated Chronic Lymphocytic Leukemia
What this study did
NCT04169737 · M.D. Anderson Cancer Center
2020-07-29 – 2028-07-09 · Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
What this study did
NCT06958705 · The First Affiliated Hospital with Nanjing Medical University
2025-12-01 – 2028-02-01 · Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)
What this study did
NCT04624633 · Jennifer R. Brown, MD, PhD
2020-12-15 – 2028-01-01 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia
What this study did
NCT06757647 · Seema Bhat
2025-05-27 – 2027-12-31 · Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
What this study did
NCT03580928 · Dana-Farber Cancer Institute
2018-08-07 – 2027-12-31 · Chronic Lymphocytic Leukemia (CLL)
What this study did
NCT04505254 · M.D. Anderson Cancer Center
2020-08-25 – 2027-06-30 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT03128879 · M.D. Anderson Cancer Center
2017-06-16 – 2027-05-31 · Chronic Lymphocytic Leukemia
What this study did
NCT04657094 · City of Hope Medical Center
2021-03-16 – 2027-02-08 · Autoimmune Hemolytic Anemia, Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Warm Antibody Autoimmune Hemolytic Anemia
What this study did
NCT04722172 · Memorial Sloan Kettering Cancer Center
2021-05-21 – 2027-02 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT05336812 · Ohio State University Comprehensive Cancer Center
2022-09-13 – 2026-10-31 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT04660045 · Weill Medical College of Cornell University
2022-05 – 2026-06 · Chronic Lymphocytic Leukemia, CLL/SLL
What this study did
NCT02337829 · Acerta Pharma BV
2015-01-12 – 2025-10-31 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT04716075 · Polish Lymphoma Research Group
2019-08-19 – 2024-07-30 · Chronic Lymphocytic Leukemia, Chronic Graft-versus-host-disease, Mantle Cell Lymphoma, Adverse Event, Response Rate
What this study did
NCT03788291 · University of Rochester
2019-03-25 – 2023-05-19 · Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
What this study did
Diffuse Large B-Cell Lymphoma
NCT04002947 · National Cancer Institute (NCI)
2019-08-05 – 2031-03-31 · Non-Hodgkin's Lymphoma, Diffuse Large B-Cell Lymphoma, DLBCL, NHL
What this study did
NCT04604067 · Swiss Cancer Institute
2021-06-25 – 2030-12 · Diffuse Large B-cell Lymphoma
What this study did
NCT05952024 · AstraZeneca
2024-07-16 – 2029-04-22 · Diffuse Large B-Cell Lymphoma
What this study did
NCT05583149 · Patrick C. Johnson, MD
2023-03-01 – 2029-03-01 · Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL, Diffuse Large B-cell Lymphoma (DLBCL), De Novo or Transformed Indolent B-cell Lymphoma, DLBCL, Nos Genetic Subtypes, T Cell/Histiocyte-rich Large B-cell Lymphoma, EBV-Positive DLBCL, Nos, Primary Mediastinal [Thymic] Large B-cell Lymphoma (PMBCL), High-Grade B-Cell Lymphoma, Nos, C-MYC/BCL6 Double-Hit High-Grade B-Cell Lymphoma, Grade 3b Follicular Lymphoma, C-MYC/BCL2 Double-Hit High-Grade B-Cell Lymphoma
What this study did
NCT04546620 · University Hospital Southampton NHS Foundation Trust
2021-10-19 – 2028-05 · Diffuse Large B Cell Lymphoma
What this study did
NCT06441097 · Ruijin Hospital
2024-12-31 – 2027-12-31 · Diffuse Large B-Cell Lymphoma
What this study did
NCT04978584 · M.D. Anderson Cancer Center
2022-03-03 – 2027-01-16 · Diffuse Large B-Cell Lymphoma
What this study did
NCT03736616 · Swedish Medical Center
2019-08-16 – 2023-09 · Diffuse Large B Cell Lymphoma
What this study did
NCT04189952 · University of Miami
2020-09-22 – 2022-03-01 · Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Marginal Zone Lymphoma
What this study did
Mantle Cell Lymphoma
NCT07910435 · University of Washington
2027-03-01 – 2038-01-01 · Mantle Cell Lymphoma
What this study did
NCT06846489 · Sun Yat-sen University
2025-04-14 – 2033-02-20 · Mantle Cell Lymphoma (MCL)
What this study did
NCT04566887 · University Health Network, Toronto
2021-03-01 – 2032-04-30 · Mantle Cell Lymphoma
What this study did
NCT07029737 · AstraZeneca
2025-09-05 – 2029-06-30 · Mantle-cell Lymphoma
What this study did
NCT05951959 · AstraZeneca
2023-12-13 – 2028-10-31 · Mantle Cell Lymphoma (MCL)
What this study did
NCT04765111 · M.D. Anderson Cancer Center
2021-06-30 – 2028-08-30 · Mantle Cell Lymphoma
What this study did
NCT04626791 · Academic and Community Cancer Research United
2021-08-03 – 2028-08-03 · Mantle Cell Lymphoma
What this study did
NCT05004064 · University College, London
2023-11-30 – 2028-06-08 · Mantle Cell Lymphoma
What this study did
NCT03863184 · Weill Medical College of Cornell University
2019-10-11 – 2028-05-30 · Mantle Cell Lymphoma
What this study did
NCT03946878 · M.D. Anderson Cancer Center
2019-08-13 – 2028-02-08 · Blastoid Variant Mantle Cell Lymphoma, CCND1 Protein Overexpression, CD20 Positive, CD5 Positive, FCER2 Negative, Pleomorphic Variant Mantle Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma, t(11;14)(q13;q32)
What this study did
NCT04783415 · City of Hope Medical Center
2021-03-26 – 2027-07-13 · Mantle Cell Lymphoma
What this study did
NCT06054776 · City of Hope Medical Center
2024-12-02 – 2027-07-13 · Mantle Cell Lymphoma
What this study did
NCT04189757 · M.D. Anderson Cancer Center
2020-08-07 – 2027-06-30 · Mantle Cell Lymphoma
What this study did
NCT04484012 · City of Hope Medical Center
2020-12-31 – 2027-02-23 · Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
What this study did
NCT04883437 · Emory University
2021-09-03 – 2027-01-15 · Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Indolent Non-Hodgkin Lymphoma, Lymphoplasmacytic Lymphoma, Lymphoproliferative Disorder, Mantle Cell Lymphoma, Marginal Zone Lymphoma
What this study did
NCT05214183 · Nordic Lymphoma Group
2021-12-15 – 2027-01 · MCL, Mantle Cell Lymphoma
What this study did
NCT04115631 · ECOG-ACRIN Cancer Research Group
2019-12-13 – 2026-12-31 · Liver Lymphoma, Mantle Cell Lymphoma
What this study did
Phase 1/2 (21)
Chronic Lymphocytic Leukemia
NCT07052695 · Inhye Ahn
2025-11-24 – 2032-12-31 · Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Lymphoma
What this study did
NCT02029443 · Acerta Pharma BV
2014-01-30 – 2027-06-09 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome, Prolymphocytic Leukemia
What this study did
NCT03492125 · MingSight Pharmaceuticals, Inc
2018-05-25 – 2023-11-28 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Aggressive Lymphoma
What this study did
NCT04419389 · Aprea Therapeutics
2021-03-02 – 2021-08-24 · Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
What this study did
Diffuse Large B-Cell Lymphoma
NCT04257578 · University of Washington
2020-12-02 – 2031-03-01 · B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma
What this study did
NCT05256641 · Jonsson Comprehensive Cancer Center
2023-01-23 – 2028-01-31 · Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma, Transformed Lymphoma, Secondary Central Nervous System Lymphoma
What this study did
NCT03571308 · University Hospital Southampton NHS Foundation Trust
2017-06-02 – 2023-08-31 · Non Hodgkin Lymphoma
What this study did
Mantle Cell Lymphoma
NCT06564038 · AstraZeneca
2025-01-30 – 2030-05-20 · Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma, Large B-cell Lymphoma, B-cell Non-Hodgkin Lymphoma
What this study did
NCT04855695 · Austin I Kim
2021-07-02 – 2027-12-31 · Mantle Cell Lymphoma, Refractory Lymphoma
What this study did
NCT02362035 · Acerta Pharma BV
2015-02-20 – 2025-10-27 · Follicular Lymphoma (FL), CLL, Small Lymphocytic Lymphoma (SLL), Richter's Syndrome, Mantle Cell Lymphoma (MCL), Indolent Non Hodgkin Lymphoma, Waldenström Macroglobulinemia, Multiple Myeloma, Hodgkin Lymphoma, Burkitt Lymphoma, Marginal Zone Lymphomas, Mediastinal Large B Cell Lymphoma, Hairy Cell Leukemia
What this study did
Relapsed/Refractory Chronic Lymphocytic Leukemia
NCT03932331 · AstraZeneca
2020-04-29 – 2026-06-24 · Phase I: Relapsed or Refractory B-cell Malignancies, Phase II Cohort A: Relapsed or Refractory Mantle Cell Lymphoma, Phase II Cohort B: Relapsed or Refractory Chronic Lymphocytic Leukemia
What this study did
NCT04502394 · Kartos Therapeutics, Inc.
2021-02-23 – 2024-03 · Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
What this study did
Other / comorbidity
NCT04961801 · Shin Mineishi
2022-03 – 2030-01 · Lymphoma, Leukemia
What this study did
NCT02180711 · Acerta Pharma BV
2014-12-29 – 2028-12-11 · Non Hodgkin Lymphoma
What this study did
NCT03571568 · BioInvent International AB
2018-05-16 – 2027-09-30 · Indolent B-Cell Non-Hodgkin Lymphoma
What this study did
Acalabrutinib in CNSLactive not recruiting
NCT04906902 · Dana-Farber Cancer Institute
2021-08-23 – 2027-01-31 · Central Nervous System Lymphoma, Refractory Central Nervous System Lymphoma, Recurrent Central Nervous System Lymphoma
What this study did
NCT02586857 · Acerta Pharma BV
2016-01-25 – 2026-04-01 · Glioblastoma Multiforme
What this study did
NCT02328014 · Acerta Pharma BV
2014-12-20 – 2025-10-30 · Non-Hodgkins Lymphoma, Multiple Myeloma, B-All
What this study did
NCT04630756 · AstraZeneca
2021-02-17 – 2025-02-27 · Advanced Haematological Malignancies
What this study did
NCT05205252 · Epizyme, Inc.
2021-12-22 – 2023-07-05 · Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy
What this study did
NCT03205046 · Acerta Pharma BV
2017-06-29 – 2019-11-20 · DLBCL, Richter Syndrome
What this study did
Phase 1 (29)
Chronic Lymphocytic Leukemia
NCT05971251 · University of Alabama at Birmingham
2023-12-18 – 2028-12-31 · Chronic Lymphocytic Leukemia
What this study did
NCT05943496 · OHSU Knight Cancer Institute
2023-10-02 – 2028-01-01 · Chronic Lymphocytic Leukemia
What this study did
NCT02157324 · Acerta Pharma BV
2014-08-18 – 2026-04-01 · Chronic Lymphocytic Leukemia
What this study did
NCT02296918 · Acerta Pharma BV
2014-12-22 – 2025-10-22 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia
What this study did
Diffuse Large B-Cell Lymphoma
NCT02112526 · Acerta Pharma BV
2014-08-07 – 2024-10-04 · Activated B-cell Diffuse Large B-Cell Lymphoma (ABC DLBCL)
What this study did
NCT03527147 · Acerta Pharma BV
2018-06-19 – 2021-03-31 · NHL, DLBCL, Non-hodgkin's Lymphoma, Diffuse Large B Cell Lymphoma
What this study did
Mantle Cell Lymphoma
NCT02717624 · Acerta Pharma BV
2016-04-20 – 2027-08-20 · Mantle Cell Lymphoma (MCL)
What this study did
NCT05495464 · M.D. Anderson Cancer Center
2022-11-18 – 2027-03-31 · Lymphoma, Mantle Cell Lymphoma
What this study did
Relapsed/Refractory Chronic Lymphocytic Leukemia
NCT03328273 · Acerta Pharma BV
2018-01-31 – 2026-08-26 · Chronic Lymphocytic Leukemia
What this study did
Other / comorbidity
NCT04462328 · Washington University School of Medicine
2021-04-29 – 2028-09-30 · Primary Central Nervous System Lymphoma
What this study did
NCT04688151 · National Health Research Institutes, Taiwan
2021-02-22 – 2025-12-31 · Primary Central Nervous System Lymphoma (PCNSL)
What this study did
NCT03198650 · AstraZeneca
2017-06-27 – 2025-09-25 · Part1: Advanced B-cell Malignancies, Part2: r/rCLL and r/rMCL, Part3: Untreated CLL
What this study did
NCT04836832 · Narendranath Epperla
2022-07-01 – 2024-12-31 · Recurrent Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Nodal Marginal Zone Lymphoma, Recurrent Splenic Marginal Zone Lymphoma, Refractory Follicular Lymphoma, Refractory Indolent Non-Hodgkin Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Nodal Marginal Zone Lymphoma, Refractory Splenic Marginal Zone Lymphoma
What this study did
NCT04768985 · AstraZeneca
2021-02-25 – 2021-05-10 · Bioequivalence
What this study did
NCT04488016 · AstraZeneca
2020-06-24 – 2021-01-20 · Bioavailability, B-cell Lymphoid Cancer
What this study did
NCT04497948 · Acerta Pharma BV
2020-09-21 – 2020-11-18 · COVID-19
What this study did
NCT04489797 · AstraZeneca
2020-07-20 – 2020-08-28 · Infectious Disease
What this study did
NCT04435483 · AstraZeneca
2020-05-22 – 2020-06-26 · Pharmacokinetics, Bioavailability
What this study did
NCT02211014 · Acerta Pharma BV
2015-02 – 2019-04-26 · Multiple Myeloma (MM)
What this study did
NCT03968848 · Acerta Pharma BV
2018-11-12 – 2019-03-29 · Hepatic Impairment, Hepatic Insufficiency, Healthy Subjects
What this study did
NCT04905043 · Acerta Pharma BV
2016-06-03 – 2016-07-11 · Healthy Volunteers
What this study did
NCT04867980 · Acerta Pharma BV
2016-04-01 – 2016-05-09 · Healthy Volunteers
What this study did
NCT04898101 · Acerta Pharma BV
2016-03-03 – 2016-04-13 · Healthy Volunteers
What this study did
NCT04867941 · Acerta Pharma BV
2014-10-21 – 2015-02-02 · Hepatic Insufficiency
What this study did
NCT04914936 · Acerta Pharma BV
2014-09-21 – 2014-10-16 · Healthy Participants
What this study did
NCT04901923 · Acerta Pharma BV
2014-03-15 – 2014-05-22 · Healthy Participants
What this study did
Phase 4 (3)
Chronic Lymphocytic Leukemia
NCT04930536 · AstraZeneca
2021-07-14 – 2023-05-02 · Chronic Lymphocytic Leukemia and Relapsed and Refractory Mantle Cell Lymphoma
What this study did
Other / comorbidity
NCT06651970 · AstraZeneca
2025-02-04 – 2032-09-30 · Chronic Lymphocytic Leukaemia, Moderate to Severe Cardiac Impairment
What this study did
MACE and BTK Inhibitorsnot yet recruiting
NCT07923162 · University Hospital, Caen
2026-12-01 – 2027-03-01 · Hematologic Cancer, MACE, BTK Inhibitors
What this study did
Early phase / not applicable (2)
Chronic Lymphocytic Leukemia
NCT05950997 · The First Affiliated Hospital with Nanjing Medical University
2024-04-16 – 2026-09-30 · Chronic Lymphocytic Leukemia
What this study did
Other / comorbidity
NCT05024006 · University of the Philippines
2020-04-23 – 2021-04-17 · Covid19
What this study did
Used as active comparator (4)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (4)
Chronic Lymphocytic Leukemia
NCT06136559 · Merck Sharp & Dohme LLC
2023-12-13 – 2032-09-07 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
Mantle Cell Lymphoma
NCT07377578 · Guangzhou Lupeng Pharmaceutical Company LTD.
2026-02-05 – 2033-01-30 · Mantle Cell Lymphoma
What this study did
NCT04662255 · Loxo Oncology, Inc.
2021-04-08 – 2030-06 · Lymphoma, Mantle-Cell
What this study did
Appears in other studies (2)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2 (1)
Chronic Lymphocytic Leukemia
NCT06520098 · VA Office of Research and Development
2025-10-01 – 2030-12-31 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
Phase 1 (1)
Chronic Lymphocytic Leukemia
NCT03666000 · Imugene Limited
2019-03-11 – 2027-06 · Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did

Competitive landscape

4 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Mantle Cell Lymphoma: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Acalabrutinib: this drugApprovedSmall moleculeBTKWeak signal
NCT02213926: Overall Response Rate (ORR) of ACP-196 (Acalabrutinib) in Subjects With Previously Treated MCL. (From the date of the first dose until 30 days after the last dose of the study drug or start of a new anti-cancer treatment, whichever came first, assessed up to approximately 4 year and 10 months. 1 cycle =28 days): ACP-196 (Acalabrutinib) — CR: 59 Participants; PR: 42 Participants; SD: 10 Participants; PD: 10 Participants; NE: 3 Participants
BortezomibApprovedSmall moleculeProteasomenot yet gradedNo reviewed efficacy summary in this indication
LenalidomideApprovedSmall moleculeCereblon E3 ubiquitin-ligase, Thalidomide Analognot yet gradedNo reviewed efficacy summary in this indication
PirtobrutinibApprovedSmall moleculeBTKnot yet gradedNo reviewed efficacy summary in this indication
Rilzabrutinib
Approved(overall)
Small moleculeBTK
Reliable signal(overall)
No reviewed efficacy summary in this indication
Sonrotoclax (Beqalzi)ApprovedSmall moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
Zanubrutinib (Brukinsa)ApprovedSmall moleculeBTKWeak signal
NCT04002297: Primary endpoint, progression-free survival: zanubrutinib plus rituximab superior to bendamustine plus rituximab (BeOne topline, 2026-06-01).
NCT03206970: Overall response rate by independent review: 72/86 (83.7%, 95% CI 74.2 to 90.8), p<0.0001 against a null rate of 40% (single arm) (CT.gov posted results).
IbrutinibPhase 3Small moleculeBTKnot yet gradedNo reviewed efficacy summary in this indication
MesutoclaxPhase 3Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(57 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Acalabrutinib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (5)
December 2026 (5)
Phase 2IgM MGUS, Waldenstrom Macroglobulinemia, Neuropathy;PeripheralActive not recruiting
Est. primary completion 2026-12-01 · NCT05065554 · CT.gov ↗
What to watch
Phase 1Primary Central Nervous System LymphomaActive not recruiting
Est. primary completion 2026-12-31 · NCT04462328 · CT.gov ↗
What to watch
Phase 1Chronic Lymphocytic LeukemiaActive not recruiting
Est. primary completion 2026-12-31 · NCT05971251 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2026-12-31 · NCT06757647 · CT.gov ↗
What to watch
Phase 2Mantle Cell LymphomaActive not recruiting
Est. primary completion 2026-12-31 · NCT04115631 · CT.gov ↗
What to watch
2027 (26)
January 2027 (4)
Phase 2Mantle Cell LymphomaActive not recruiting
Est. primary completion 2027-01 · NCT05214183 · CT.gov ↗
What to watch
Phase 1Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2027-01-01 · NCT05943496 · CT.gov ↗
What to watch
Phase 2Diffuse Large B-Cell LymphomaActive not recruiting
Est. primary completion 2027-01-16 · NCT04978584 · CT.gov ↗
What to watch
Phase 1/2Diffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2027-01-31 · NCT05256641 · CT.gov ↗
What to watch
February 2027 (5)
Phase 2Chronic Lymphocytic LeukemiaActive not recruiting
Est. primary completion 2027-02 · NCT04722172 · CT.gov ↗
What to watch
Phase 4Hematologic Cancer, MACE, BTK InhibitorsNot yet recruiting
Est. primary completion 2027-02-01 · NCT07923162 · CT.gov ↗
What to watch
Phase 3Lymphoma, Mantle CellActive not recruiting
Est. primary completion 2027-02-15 · NCT02972840 · CT.gov ↗
What to watch
Phase 3Diffuse Large B-Cell LymphomaActive not recruiting
Est. primary completion 2027-02-22 · NCT04529772 · CT.gov ↗
What to watch
Phase 2Mantle Cell LymphomaActive not recruiting
Est. primary completion 2027-02-23 · NCT04484012 · CT.gov ↗
What to watch
March 2027 (1)
Phase 1Mantle Cell LymphomaActive not recruiting
Est. primary completion 2027-03-31 · NCT05495464 · CT.gov ↗
What to watch
April 2027 (1)
Phase 3Chronic Lymphocytic LeukemiaActive not recruiting
Est. primary completion 2027-04-30 · NCT03836261 · CT.gov ↗
What to watch
May 2027 (1)
Phase 2Chronic Lymphocytic LeukemiaActive not recruiting
Est. primary completion 2027-05-31 · NCT03128879 · CT.gov ↗
What to watch
June 2027 (3)
Phase 1/2Mantle Cell LymphomaRecruiting
Est. primary completion 2027-06-30 · NCT04855695 · CT.gov ↗
What to watch
Phase 2Mantle Cell LymphomaActive not recruiting
Est. primary completion 2027-06-30 · NCT04189757 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaActive not recruiting
Est. primary completion 2027-06-30 · NCT04505254 · CT.gov ↗
What to watch
July 2027 (2)
Phase 2Mantle Cell LymphomaRecruiting
Est. primary completion 2027-07-13 · NCT06054776 · CT.gov ↗
What to watch
Phase 3Chronic Lymphocytic LeukemiaActive not recruiting
Est. primary completion 2027-07-15 · NCT05057494 · CT.gov ↗
What to watch
August 2027 (2)
Phase 3CLL/SLLRecruiting
Est. primary completion 2027-08 · NCT06319456 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2027-08-10 · NCT04941716 · CT.gov ↗
What to watch
September 2027 (2)
Phase 2Marginal Zone LymphomaActive not recruiting
Est. primary completion 2027-09-15 · NCT04646395 · CT.gov ↗
What to watch
Phase 1/2Indolent B-Cell Non-Hodgkin LymphomaRecruiting
Est. primary completion 2027-09-30 · NCT03571568 · CT.gov ↗
What to watch
October 2027 (1)
Phase 2Diffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2027-10-12 · NCT04002947 · CT.gov ↗
What to watch
November 2027 (1)
Phase 2Diffuse Large B-Cell LymphomaActive not recruiting
Est. primary completion 2027-11 · NCT04546620 · CT.gov ↗
What to watch
December 2027 (3)
Phase 2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2027-12-01 · NCT06958705 · CT.gov ↗
What to watch
Phase 2Diffuse Large B-Cell LymphomaNot yet recruiting
Est. primary completion 2027-12-31 · NCT06441097 · CT.gov ↗
What to watch
Phase 2Mantle Cell LymphomaRecruiting
Est. primary completion 2027-12-31 · NCT07029737 · CT.gov ↗
What to watch
2028 (15)
February 2028 (1)
Phase 2Mantle Cell LymphomaActive not recruiting
Est. primary completion 2028-02-08 · NCT03946878 · CT.gov ↗
What to watch
March 2028 (3)
Phase 3Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2028-03 · NCT06428019 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaActive not recruiting
Est. primary completion 2028-03-01 · NCT04560322 · CT.gov ↗
What to watch
Phase 2Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma …Recruiting
Est. primary completion 2028-03-01 · NCT04404088 · CT.gov ↗
What to watch
May 2028 (1)
Phase 3Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2028-05 · NCT05197192 · CT.gov ↗
What to watch
June 2028 (2)
Phase 2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2028-06-05 · NCT07014917 · CT.gov ↗
What to watch
Phase 2Richter SyndromeActive not recruiting
Est. primary completion 2028-06-30 · NCT03899337 · CT.gov ↗
What to watch
July 2028 (1)
Phase 2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2028-07-09 · NCT04169737 · CT.gov ↗
What to watch
August 2028 (1)
Phase 2Mantle Cell LymphomaActive not recruiting
Est. primary completion 2028-08-30 · NCT04765111 · CT.gov ↗
What to watch
September 2028 (1)
Phase 2Mantle Cell LymphomaActive not recruiting
Est. primary completion 2028-09 · NCT04566887 · CT.gov ↗
What to watch
October 2028 (1)
Phase 2Mantle Cell LymphomaActive not recruiting
Est. primary completion 2028-10-31 · NCT05951959 · CT.gov ↗
What to watch
November 2028 (2)
Phase 2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2028-11-11 · NCT03516617 · CT.gov ↗
What to watch
Phase 2Phase 2 Study, MCL, BTKi, Rituximab, GlofitamabRecruiting
Est. primary completion 2028-11-24 · NCT07257055 · CT.gov ↗
What to watch
December 2028 (2)
Phase 2CLL/SLLRecruiting
Est. primary completion 2028-12 · NCT04523428 · CT.gov ↗
What to watch
Phase 1/2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2028-12-31 · NCT07052695 · CT.gov ↗
What to watch
2029 (7)
January 2029 (2)
Phase 3Hematological Malignancies, Platelet Transfusion Refractoriness (PTR), HLA AntibodiesNot yet recruiting
Est. primary completion 2029-01-01 · NCT07635511 · CT.gov ↗
What to watch
Phase 2Diffuse Large B-Cell LymphomaActive not recruiting
Est. primary completion 2029-01-30 · NCT04604067 · CT.gov ↗
What to watch
February 2029 (1)
Phase 3Diffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2029-02 · NCT05820841 · CT.gov ↗
What to watch
April 2029 (2)
Phase 2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2029-04-14 · NCT07582159 · CT.gov ↗
What to watch
Phase 2Diffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2029-04-22 · NCT05952024 · CT.gov ↗
What to watch
May 2029 (1)
Phase 2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2029-05-01 · NCT07024706 · CT.gov ↗
What to watch
July 2029 (1)
Phase 2/3CLLRecruiting
Est. primary completion 2029-07-31 · NCT03868722 · CT.gov ↗
What to watch
2030 (1)
May 2030 (1)
Phase 1/2Mantle Cell LymphomaRecruiting
Est. primary completion 2030-05-20 · NCT06564038 · CT.gov ↗
What to watch
2032 (1)
September 2032 (1)
Phase 4Chronic Lymphocytic Leukaemia, Moderate to Severe Cardiac ImpairmentRecruiting
Est. primary completion 2032-09-30 · NCT06651970 · CT.gov ↗
What to watch
2033 (2)
January 2033 (1)
Phase 2Mantle Cell LymphomaNot yet recruiting
Est. primary completion 2033-01-01 · NCT07910435 · CT.gov ↗
What to watch
February 2033 (1)
Phase 2Mantle Cell LymphomaRecruiting
Est. primary completion 2033-02-10 · NCT06846489 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

29 July 2025Filing submittedsNDA submitted for venetoclax plus acalabrutinib in previously untreated CLL
US, FDA · Source ↗